Literature DB >> 8763008

[Pulmonary valve replacement for endocarditis. Apropos of 2 cases].

D Chatel1, D Longrois, C Lenormand, S Calvat, J F Timsit, E Brochet, A Boccara, U Hvass.   

Abstract

The authors report two cases of pulmonary valve endocarditis which required emergency surgical treatment. A 74 year old patient with trivalvular endocarditis (pulmonary, aortic, mitral), due to Sptreptococcus D bovis, developed cardiogenic shock with acute pulmonary oedema and underwent double aortic and pulmonary valve replacement with Carpentier-Edwards prostheses and simple resection of a mitral valve vegetation. Another 36 year old drug addict developed isolated pulmonary valve endocarditis due to Staphylococcus aureus infection complicated by pulmonary regurgitation with right ventricular failure and by septic pulmonary embolism with persistent sepsis: he underwent pulmonary valve replacement with a Bravo 300 bioprosthesis. The postoperative course was uncomplicated in both cases, with interruption of the infection and normalisation of the haemodynamic status. The insidious and severe nature of pulmonary valve endocarditis is demonstrated by these two cases, confirming previous reports which have underlined the poor prognosis of this condition. Surgery has been shown to be effective and well tolerated and should be integrated early in the therapeutic strategy, the results being all the better when an aggressive attitude is taken.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763008

Source DB:  PubMed          Journal:  Arch Mal Coeur Vaiss        ISSN: 0003-9683


  2 in total

1.  Right ventricular and septal anomalies complicated by subacute bacterial endocarditis.

Authors:  Q C He; Y Q Wang; B T Zhong; Z L Chen; J G Guo; W W Ye
Journal:  Tex Heart Inst J       Date:  2000

2.  Cardiac septic pulmonary embolism: A retrospective analysis of 20 cases in a Chinese population.

Authors:  Xin Yu Song; Shan Li; Jian Cao; Kai Xu; Hui Huang; Zuo Jun Xu
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.